Chongqing Zhifei Biological Products Co., Ltd. (“Zhifei” or “the Company” for short) has its presence in biological product industry in 2002. The Company achieved an operating income of RMB10.59 billion in 2019 with the support of its nearly 3,000 employees based on its registered capital of RMB1.6 billion and total assets of RMB13.6 billion.In September 2010, Zhifei was listed on the Shenzhen Stock Exchange (stock code: 300122), becoming the first privately-run vaccine enterprise listed on ChiNext. Zhifei has five wholly-owned subsidiaries and a joint-stock subsidiary, of which Beijing ZhifeiLvzhu Biopharmaceutical Co., Ltd. and Anhui ZhifeiLongcom Biopharmaceutical Co., Ltd. are new high-tech enterprises.
As a high-tech biological enterprise integrating the R&D, production, marketing, distribution as well as import & export, Zhifei mainly engages in the production of vaccines for human use, which is one of seven strategic emerging industries of China and has a broad development prospect. The commercially available products of the Company include Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) (Ekear®), Haemophilus Influenzae Type b Vaccine (XiFeiBei®), Group ACYW135 Meningococcal Polysaccharide Vaccine (Menwayc®), Mycobacterium Vaccae for Injection (Vaccae®), Meningococcal Group A and Group C Polysaccharide Conjugate Vaccine (Mening A Con®), and other independently developed products. Meantime, Zhifei is the sole distributor of the vaccines of Merck Sharp &Dohme(MSD) such as HPV4(Gradasil),HPV9(Gradasil 9),5-valent rotavirus vaccine(Rotateq),23-valent Pneumonia vaccine(Pneumovax 23),Hepatitis A vaccine(Vaqta).